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Summary.-A combination of misonidazole and MTDQ (6,6'-methylene-bis-2,2,4
trimethyl-1,2-dihydroquinoline) has been tested for its radiation-sensitizing proper-
ties and cytotoxicity, using Chinese hamster V79 cells cultured in vitro.
Both compounds sensitize hypoxic cells to the effects of X-rays, and when used in
combination their sensitizing properties are additive. By contrast, the presence of
MTDQ completely inhibits the cytotoxicity that misonidazole exhibits towards
hypoxic cells.
These experiments shed some light on the mechanism of action of electron-affinic
hypoxic cell sensitizers, and the combination of radiosensitizers suggested may have
an application in human cancer radiotherapy by eliminating the neurotoxicity
experienced by patients receiving misonidazole during radiotherapy.
MISONIDAZOLE (MIS) is an electron-
affinic compound that selectively sensi-
tizes mammalian cells to the lethal effects
of X- and y-rays, and is already in use in
clinical trials as an adjunct to radio-
therapy (Asquith et al., 1974; Brown,
1975; Fowler et al., 1976). MTDQ
(6,6'-methylene-bis-2,2,4 trimethyl-1, 2-di-
hydroquinoline) is an antioxidant that
was initially developed as a food additive,
but has recently been the subject of pre-
liminary clinical investigations in Hun-
gary and limited in vitro experimentation
in the United States (Bar et al., 1975,
1977; Hall et al., 1978).
It has been shown in numerous bio-
logical systems that hypoxic cells are
relatively resistant to killing by sparsely
ionizing radiations such as X- or y-rays.
It is not known with certainty whether
human tumours contain viable hypoxie
cells that limit their curability by ionizing
radiations, but from histological evidence
and by analogy with animal tumours it is
likely that they do (Thomlinson & Gray,
1955; Evans & Naylor, 1963). Various
methods have been proposed to counter
the problem of hypoxic cells. These in-
clude the use of high-pressure oxygen
chambers, hyperthermia, radiations with
a high linear-energy-transfer and, most
recently, the introduction of chemical
radiosensitizers that interact with radi-
ation to increase specifically the sensitivity
of hypoxic cells while not affecting the
response of normal cells (Fowler et al.,
1976; Churchill-Davidson, 1966). A num-
ber of compounds have been tested as
radiosensitizers in vitro and in vivo.
Chapman et al. (1973) linked the radio-
sensitizing properties to the nitro group,
whilst Adams and his colleagues defined
the properties necessary for a compound
to be used clinically, and established the
relationship between electron affinity and
radiosensitizing efficiency (Adams, 1973;
Adams et al., 1976). As a result of this
diverse experimentation, the nitroimid-
azoles have been shown to possess the
necessary properties and have emerged as
leading candidates for clinical use. Cur-
rently, 2 of these compounds, misonid-
azole and metronidazole, are undergoing
clinical trials in a number of differentMISONIDAZOLE AND MTDQ IN COMBINATION
countries (Urtasun et al., 1976; Thomlin-
son et al., 1976; Dische et al., 1977).
In addition to preferentially radio-
sensitizing hypoxic cells, the nitroimid-
azoles also exhibit a temperature-depend-
ent cytotoxicity towards cells deficient in
oxygen (Hall & Roizin-Towle, 1975; Mohin-
dra & Rauth 1976; Stratford & Adams,
1977; Sutherland, 1974; Hall et at., 1977).
Generally speaking, 2-nitroimidazoles
have been demonstrated to be more cyto-
toxic than the corresponding 5-nitro-
imidazoles. It has been postulated that
the cytotoxicity is due to intermediate
metabolites of the nitroreductase enzyme
systems which only function in the ab-
sence of oxygen. These enzymes catalyse
the reduction of the nitro group to the
amino group. Two of the known metabo-
lites, namely the nitroso and hydroxyl-
amine intermediates, are known carcino-
gens and cytotoxic agents (Gillette, 1971;
Gillette et al., 1968; Biaglow et al., 1976;
Hall et al., 1977; Willson et al., 1974).
The clinical use of MIS in radiotherapy
patients has been limited because of the
occurrence of peripheral neuropathy and
symptoms arising from central-nervous-
system damage when large doses are given
repeatedly. It is thought that the peri-
pheral neuropathy is a consequence of
damage to the myelin sheath surrounding
the nervous fibres (Urtasun et al., 1978;
Hirst et al., 1978; Dische et al., 1977). It
has not been established whether there is
a correlation between the neurological
toxicity found in patients and the cyto-
toxicity towards hypoxic cells that has
been shown with cell cultures in vitro.
Recent experiments have shown that
MTDQ is a radiosensitizer with an effec-
tiveness very similar to that of MIS (Hall
et al., 1979). Its use is limited because
relatively low concentrations only can be
obtained in the human. However, it
shows a very low toxicity compared with
MIS and it may be of interest for this
reason (Bar et al., 1975). The present com-
munication describes experiments involv-
ing the simultaneous use of MIS and
MTDQ in order to determine the sensi-
tizing properties and the cytotoxicity of
this combination of 2 widely different
agents.
MATERIALS AND METHODS
Standard culture techniques wvere used to
grow Chinese hamster V79 cells in GIBCO
F-10 culture medium, supplemented with
10% foetal calf serum, and antibiotics (Ham
& Puck, 1962).
For radiation or cytotoxicity experiments
under hypoxia, cells were treated in suspen-
sion in glass ampoules. To induce hypoxia, a
large number ofcells was crowded into a small
volume of medium so that 02 was reduced to
a low level by cell metabolism and respiration.
This method has been widely used, and
described in detail elsewhere (Hall et al.,
1974). The essential steps are as follows: cells
from a number of actively growing, partially
confluent, stock flasks were harvested by
trypsinization, washed to remove excess
trypsin. and the concentration of cells deter-
mined by counting with a Coulter electronic
cell counter. This cell suspension was then
divided into several parts and the cell con-
centration in each adjusted to 2x 106 cells/
ml, adding one or another drug at an appro-
priate concentration according to the plan of
the particular experiment. MIS dissolved
readily in the cell-culture medium, but in the
case of MTDQ, the drug had first to be
dissolved in a solvent such as Tween-80. This
solution was then diluted with medium until
the concentration of the Tween-80 repre-
sented no more than 0 1% of the culture
medium; this was necessary because the
solventper se was found to be cytotoxic. From
each of the cell suspensions, containing
various concentrations of one drug, 2 drugs,
or no drug at all, series of glass ampoules
wvere filled by pipetting 1 ml of the cell sus-
pension into each. These ampoules were then
handled in the following way in order to
render the cells hypoxic. The ampoules were
flushed with high-purity N2 plus 500 CO2 in
order to displace the air above the cell sus-
pension. Each ampoule was heat-sealed
before it was transferred to a water bath at
37 5°C, where it was continuously shaken and
tumbled end-to-end to keep the cells in sus-
pension. This procedure was maintained for
1 h to allow the cells to scavenge the 02
dissolved in the medium by normal respira-
tion and metabolism. Proof that this system
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produces adequate levels of hypoxia is
evidenced by an oxygen enhancement ratio
(OER) in excess of 3 when aerated and
hypoxic cells are exposed to acute doses of
60Cobalt y-rays. A parallel series of ampoules
was filled with cells at a concentration of
104/ml; these were gassed with a mixture of
air and 5% CO2 before being heat-sealed.
Because of the lower number of cells, these
ampoules remained aerated throughout. For
the periods oftime used in these experiments,
the plating efficiency for both groups of cells,
aerated and hypoxic, remained high (typically
70%) and unaffected by the experimental
conditions used.
Following this procedure the cells were
irradiated with y-rays, or subjected to various
periods in the water bath at 37 5°C to assess
cytotoxicity. The source of y-rays was a
60Cobalt teletherapy unit, directed vertically
upwards so that the cells were irradiated
through the bottom ofthe glass ampoules. At
a treatment distance of 40 cm the dose rate
was computed to be 2-05 Gy/min. Heat treat-
ments were carried out by immersing the
ampoules in a water bath at 37 5°C controlled
to +0O10C; the ampoules were continuously
tumbled and shaken during this heat treat-
ment to prevent attachment ofthe cells to the
glass surface.
At the conclusion of all treatments, each
ampoule was agitated on a vortex mixer to
resuspend the cells, after which it was opened
and various aliquots of the cell suspension
plated into Falcon tissue-culture flasks con-
taining fresh growth medium. After incuba-
tion for 8 days at 37-5°C, cells were fixed and
stained, and the number of macroscopic
colonies counted by a projection technique.
RESULTS
Fig. 1 and 2 show the results of experi-
ments in which Chinese hamster V79 cells
were exposed to graded doses of 60Cobalt
y-rays under aerated and hypoxic con-
ditions, in the presence of various concen-
trations of MIS or MTDQ or a combina-
tion of both. In Fig. 3, the enhancement
ratio is plotted as a function of drug con-
centration for MTDQ alone, or both in
combination. The enhancement ratio is
defined as the ratio ofdoses in the absence
and presence of the drug required to pro-
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FIG. 1. Survival data for Chinese hamster
V79 cells exposed to graded doses of 60Co
y-rays under aerated or hypoxic conditions
in the presence or absence of various con-
centrations of misonidazole (MIS), MTDQ,
or both in combination. Standard errors
are shown where larger than the points
plotted. The curves were fitted by eye.
duce the same biological effect; the values
plotted in Fig. 3 were taken from the
experimental data in Figs. 1 and 2.
Fig. 4 shows the result ofan experiment
in which Chinese hamster V79 cells were
exposed for various periods of time at
37-5°C to MTDQ alone, MIS alone, or a
combination of both. It is evident from
the figure that 0 1 mm of MTDQ does not
show significant cytotoxicity, whilst the
addition of this quantity of the anti-
oxidant completely blocks the substantial
cytotoxicity produced by 5 mm of MIS.
The data in Fig. 4 are from one large self-
contained experiment, which has however
been repeated 5 times with essentially
similar results.
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FIG. 2. Continuation of Fig. 1 (q.v.) TIME (h) Ot 37.50 C
CONCENTRATION OF SENSITIZER ImM)
FIG. 3. Enhancement ratios as a function of
drug concentration calculated from the
data of Fig. 1 and 2. In the case of the com-
bination of both drugs, the concentration
plotted is the sum of01ImM MTDQ plus the
various amounts ofMIS.
DISCUSSION
The data presented in this paper show
that MTDQ is a radiosensitizer equal or
slightly superior to MIS at the same con-
centration. However, used alone, MTDQ
is not a serious rival, competitor or alter-
native to MIS because the concentrations
that can be obtained in vivo are limited by
the solubility of the drug. By contrast, the
FIG. 4.-The fraction of cells surviving
hypoxia for various times at 37.5°C with
MIS, MTDQ, or a combination of both.
A,Nodrug. @,5mMMIS. Q,OlmMMTDQ. 0, 5mm MIS+O lmM MTDQ. A, 5mM
MIS+ O+lmM MTDQ.
combination of MTDQ and MIS yield
results that are very interesting, and there
may be considerable promise in simul-
taneous use of the 2 drugs.
First, the enhancement ratios (ERs)
obtainedwith the 2 drugs are additive even
whentheir concentrations differ by afactor
of 50. Thisis not the case when 2 electron-
affinic drugs, PNAP and MIS, are added,
or when oxygen is added to either agent.
In this situation, partial additivity is seen
only if the combined ERs of the 2 com-
pounds is less than 1M6. When either (or
both) of the 2 compounds has an ER
greater than 16, the ER of the combina-
tion is determined solely by the compound
with the higher ER (McNally & de Ronde,
1978). For example, if5mM MIS (ER= 2.4)
and 0 4mM PNAP (ER=16) are com-
bined, the resulting ER is only 2-4. The
fact that the effects of MTDQ and MIS
are additive, even when present in very
different quantities, strongly suggests that
their sites of action are different.
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Second, the addition of MTDQ inhibits
the cytotoxicity which MIS shows to-
wards hypoxic cells, even when MTDQ is
present at the concentration 1/50 that of
the nitroimidazole. If, indeed, the cyto-
toxicity of MIS towards hypoxic cells is
related to the neurological toxicity of
large doses of this drug in man, the
exciting possibility is opened up that
MTDQ may be able to reduce or eliminate
this troublesome side effect. What few
data are available for MTDQ in the
Hungarian literature indicate very low
toxicity in man. There are reports that
daily doses of 1300 mg have been ad-
ministered continuously for periods of 100
days with no untoward side effects, apart
from transient nausea and vomiting (Bar
et al., 1975).
These preliminary in vitro experiments
indicate that the combination of these 2
agents shows additivity of radiosensi-
tizing effects whilst the cytotoxicity is less
than that ofMIS alone. It is interesting to
speculate on the mechanism of this inter-
action. A previous report from this
laboratory (Hall et al., 1977) suggested
that both the radiosensitizing and cyto-
toxic properties of MIS on hypoxic cells
are mediated via a common metabolite,
the RN02- radical anion (Mason &
Holtzman, 1975; Wardman & Clarke,
1976). When cysteamine, a free-radical
scavenger, was added in equimolar con-
centrations with MIS both the radiosensi-
tization and cytotoxicity of MIS were
reversed. MTDQ, on the other hand, only
reverses the cytotoxicity ofMIS. Since the
metabolites of MIS have been implicated
as the agents responsible for its toxicity
(Hall et al., 1977; Willson et al., 1974) and
the radiosensitizing properties are un-
affected, it appears that the site of inter-
action is not the RN02- radical, but is
prior to the radical's formation. The
enzyme systems responsible for metabo-
lism of drugs exhibit little substrate
specificityintheiraction (Mannering, 1971;
Fouts & Brodie, 1957). Because of their
inherent lack of specifity, it is possible
that a drug may interact to inhibit or alter
the metabolism of a second drug. In Fig. 4
MTDQ protects against the cytotoxic
effects of MIS even when it is present at a
concentration 1/50 that of the nitro-
imidazole. The effect is dramatic; the
fraction of cells surviving a 5h treatment
with MIS at 5 mm is increased x 100 by
the addition of MTDQ at 01 mm. Even
when the concentration of MTDQ is
decreased to 0-01 mm it still exerts some
inhibition of the toxicity of misonidazole.
Because of its structure and insolubility
and its action at much lower concentra-
tions, MTDQ may compete with MIS for
metabolic enzymes. In this way the
sensitizing NO2 group of MIS would re-
main unaffected but the reduction neces-
sary for expression of cytotoxicity would
be blocked.
Since MTDQ is an antioxidant, it will
be interesting to discover whether other
antioxidants commonly used as food
additives, such as BHT*, BHAt and
ethoxyquin, can also inhibit the cytotoxic
action of MIS (Wattenberg, 1972). At all
events the combination of agents whose
mode of action may be different offers an
exciting extension to the study ofthe field
of hypoxic cell radiosensitizers.
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